Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH Trial)

Titre officiel

Platelet Transfusions in Hematopoietic Stem Cell Transplantation - The PATH Phase III Trial

Sommaire:

Cette étude vise à vérifier l’hypothèse voulant qu’une stratégie prévoyant l’administration prophylactique de l’acide tranexamique (ATX) par voies orale ou intraveineuse en association avec des transfusions thérapeutiques de plaquettes (au besoin) soit sûre et plus efficace que les transfusions prophylactiques de plaquettes chez des patients devant subir une autogreffe de cellules souches hématopoïétiques.

Description de l'essai

Primary Outcome:

• WHO (World Health Organization) bleeding events of Grade 2 or higher

Secondary Outcome:

• WHO bleeding events of Grade 3 or 4
• Time from randomization to bleeding of WHO events Grade 2 or higher
• Number of days with bleeding of WHO bleeding events Grade 2 or higher
• Bleeding Severity Measurement Scale (BSMS) for bleeding events Grade 2 or higher
• Number of platelet and/or red blood cell transfusions
• Adverse reactions related to tranexamic acid
• Venous thromboembolism grade 2 or higher
• Adverse reactions related to platelet transfusion
• Time to platelet count recovery
• Number of days with a platelet count < 10 x 109/L
• LOS (Length of hospital stay)
• Transplant related outcome: Bearman Scoring System for Organ Toxicity following HSCT
• Transplant related outcome: Incidence of infections at Day 30 following ASCT
• Transplant related outcome: Mortality at Day 30 and 180
• Economic Analyses
• Quality of Life Measure: FACT-Thrombocytopenia 18
• Quality of Life Measure: FACT- BMT
• Quality of Life Measure: GAD-7
• Quality of Life Measure: EQ-5D

In Canada, over 1,500 autologous hematopoietic stem cell transplantations (ASCT) are performed annually for hematologic malignancies. It is currently standard practice to provide a prophylactic transfusion of platelets to prevent bleeding when the daily measured platelet count is less than 10 x 109/L. A patient may require up to six adult platelet doses during the post-transplant period. However, the true benefit of prophylactic platelet transfusions in the ASCT setting is unclear and has been called into question by several recent studies. Prophylactic platelet transfusions may not only be unnecessary, they may be detrimental to the patient. Among blood products, platelet transfusions are associated with the highest risk of both infectious and non-infectious complications: this would include bacterial infections and allergic /febrile reactions. Moreover, the potential overuse of platelet products places a significant burden on a scarce health care resource that is provided through volunteer donations. An alternative strategy to prevent bleeding and reduce the need for platelet transfusions involves administering Tranexamic Acid, an antifibrinolytic agent to stabilize blood clots and reduce bleeding. Tranexamic Acid is safe and effective in many clinical scenarios, and may be a reasonable alternative for prophylactic platelet transfusions. In the setting of ASCT, Tranexamic Acid may reduce bleeding and further enhance a strategy of therapeutic platelet transfusions where platelets are administered only in the event of active bleeding symptoms. The effect of prophylactic platelet transfusions and Tranexamic Acid on clinical, quality of life and economic outcomes in patients receiving ASCT is unknown. The primary aim of this research program is to perform a randomized controlled trial to determine whether a strategy of prophylactic Tranexamic Acid (with therapeutic platelet transfusions) is safe and effective compared to prophylactic platelet transfusions in patients undergoing ASCT. A pilot trial demonstrated feasibility by successfully recruiting 100 patients and these patients will be rolled over into the phase III study. The treatment assignment and bleeding outcomes for these patients remain blinded.

Voir cet essai sur ClinicalTrials.gov